Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 190

1.

Non-canonical AR activity facilitates endocrine resistance in breast cancer.

Chia K, Milioli H, Portman N, Laven-Law G, Coulson R, Yong A, Segara D, Parker A, Caldon CE, Deng N, Swarbrick A, Tilley WD, Hickey TE, Lim E.

Endocr Relat Cancer. 2019 Feb 1;26(2):251-264. doi: 10.1530/ERC-18-0333.

PMID:
30557851
2.

Patient-derived Models Reveal Impact of the Tumor Microenvironment on Therapeutic Response.

Shafi AA, Schiewer MJ, de Leeuw R, Dylgjeri E, McCue PA, Shah N, Gomella LG, Lallas CD, Trabulsi EJ, Centenera MM, Hickey TE, Butler LM, Raj G, Tilley WD, Cukierman E, Knudsen KE.

Eur Urol Oncol. 2018 Sep;1(4):325-337. doi: 10.1016/j.euo.2018.04.019. Epub 2018 Jun 6.

PMID:
30467556
3.

Improved relapse-free survival on aromatase inhibitors in breast cancer is associated with interaction between oestrogen receptor-α and progesterone receptor-b.

Snell CE, Gough M, Liu C, Middleton K, Pyke C, Shannon C, Woodward N, Hickey TE, Armes JE, Tilley WD.

Br J Cancer. 2018 Nov;119(11):1316-1325. doi: 10.1038/s41416-018-0331-3. Epub 2018 Nov 9.

PMID:
30410061
4.

A reciprocal feedback between the PDZ binding kinase and androgen receptor drives prostate cancer.

Warren AY, Massie CE, Watt K, Luko K, Orafidiya F, Selth LA, Mohammed H, Chohan BS, Menon S, Baridi A, Zhao W, Escriu C, Pungsrinont T, D'Santos C, Yang X, Taylor C, Qureshi A, Zecchini VR, Shaw GL, Dehm SM, Mills IG, Carroll JS, Tilley WD, McEwan IJ, Baniahmad A, Neal DE, Asim M.

Oncogene. 2018 Sep 20. doi: 10.1038/s41388-018-0501-z. [Epub ahead of print]

PMID:
30237440
5.

A patient-derived explant (PDE) model of hormone-dependent cancer.

Centenera MM, Hickey TE, Jindal S, Ryan NK, Ravindranathan P, Mohammed H, Robinson JL, Schiewer MJ, Ma S, Kapur P, Sutherland PD, Hoffmann CE, Roehrborn CG, Gomella LG, Carroll JS, Birrell SN, Knudsen KE, Raj GV, Butler LM, Tilley WD.

Mol Oncol. 2018 Sep;12(9):1608-1622. doi: 10.1002/1878-0261.12354. Epub 2018 Aug 16.

6.

Androgen Receptor Signalling Promotes a Luminal Phenotype in Mammary Epithelial Cells.

Tarulli GA, Laven-Law G, Shehata M, Walters KA, Denis IM, Rahman MM, Handelsman DJ, Dean NR, Tilley WD, Hickey TE.

J Mammary Gland Biol Neoplasia. 2018 Aug 12. doi: 10.1007/s10911-018-9406-2. [Epub ahead of print]

PMID:
30099649
7.

Patient-derived Models of Abiraterone- and Enzalutamide-resistant Prostate Cancer Reveal Sensitivity to Ribosome-directed Therapy.

Lawrence MG, Obinata D, Sandhu S, Selth LA, Wong SQ, Porter LH, Lister N, Pook D, Pezaro CJ, Goode DL, Rebello RJ, Clark AK, Papargiris M, Van Gramberg J, Hanson AR, Banks P, Wang H, Niranjan B, Keerthikumar S, Hedwards S, Huglo A, Yang R, Henzler C, Li Y, Lopez-Campos F, Castro E, Toivanen R, Azad A, Bolton D, Goad J, Grummet J, Harewood L, Kourambas J, Lawrentschuk N, Moon D, Murphy DG, Sengupta S, Snow R, Thorne H, Mitchell C, Pedersen J, Clouston D, Norden S, Ryan A, Dehm SM, Tilley WD, Pearson RB, Hannan RD, Frydenberg M, Furic L, Taylor RA, Risbridger GP.

Eur Urol. 2018 Nov;74(5):562-572. doi: 10.1016/j.eururo.2018.06.020. Epub 2018 Jul 23.

PMID:
30049486
8.

miR-200/375 control epithelial plasticity-associated alternative splicing by repressing the RNA-binding protein Quaking.

Pillman KA, Phillips CA, Roslan S, Toubia J, Dredge BK, Bert AG, Lumb R, Neumann DP, Li X, Conn SJ, Liu D, Bracken CP, Lawrence DM, Stylianou N, Schreiber AW, Tilley WD, Hollier BG, Khew-Goodall Y, Selth LA, Goodall GJ, Gregory PA.

EMBO J. 2018 Jul 2;37(13). pii: e99016. doi: 10.15252/embj.201899016. Epub 2018 Jun 5.

9.

New Opportunities for Targeting the Androgen Receptor in Prostate Cancer.

Centenera MM, Selth LA, Ebrahimie E, Butler LM, Tilley WD.

Cold Spring Harb Perspect Med. 2018 Dec 3;8(12). pii: a030478. doi: 10.1101/cshperspect.a030478. Review.

PMID:
29530945
10.

The Magnitude of Androgen Receptor Positivity in Breast Cancer Is Critical for Reliable Prediction of Disease Outcome.

Ricciardelli C, Bianco-Miotto T, Jindal S, Butler LM, Leung S, McNeil CM, O'Toole SA, Ebrahimie E, Millar EKA, Sakko AJ, Ruiz AI, Vowler SL, Huntsman DG, Birrell SN, Sutherland RL, Palmieri C, Hickey TE, Tilley WD.

Clin Cancer Res. 2018 May 15;24(10):2328-2341. doi: 10.1158/1078-0432.CCR-17-1199. Epub 2018 Mar 7.

PMID:
29514843
11.

Novel Selective Agents for the Degradation of Androgen Receptor Variants to Treat Castration-Resistant Prostate Cancer.

Ponnusamy S, Coss CC, Thiyagarajan T, Watts K, Hwang DJ, He Y, Selth LA, McEwan IJ, Duke CB, Pagadala J, Singh G, Wake RW, Ledbetter C, Tilley WD, Moldoveanu T, Dalton JT, Miller DD, Narayanan R.

Cancer Res. 2017 Nov 15;77(22):6282-6298. doi: 10.1158/0008-5472.CAN-17-0976. Epub 2017 Oct 4.

12.

Novel Androgen Receptor Coregulator GRHL2 Exerts Both Oncogenic and Antimetastatic Functions in Prostate Cancer.

Paltoglou S, Das R, Townley SL, Hickey TE, Tarulli GA, Coutinho I, Fernandes R, Hanson AR, Denis I, Carroll JS, Dehm SM, Raj GV, Plymate SR, Tilley WD, Selth LA.

Cancer Res. 2017 Jul 1;77(13):3417-3430. doi: 10.1158/0008-5472.CAN-16-1616. Epub 2017 May 4.

13.

Disrupting Androgen Receptor Signaling Induces Snail-Mediated Epithelial-Mesenchymal Plasticity in Prostate Cancer.

Miao L, Yang L, Li R, Rodrigues DN, Crespo M, Hsieh JT, Tilley WD, de Bono J, Selth LA, Raj GV.

Cancer Res. 2017 Jun 1;77(11):3101-3112. doi: 10.1158/0008-5472.CAN-16-2169. Epub 2017 Mar 16.

14.

Corrigendum to "Comprehensive assessment of estrogen receptor beta antibodies in cancer cell line models and tissue reveals critical limitations in reagent specificity" [Mol. Cell Endocrinol. 440 (2016) 138-150].

Nelson AW, Groen AJ, Miller JL, Warren AY, Holmes KA, Tarulli GA, Tilley WD, Katzenellenbogen BS, Hawse JR, Gnanapragasam VJ, Carroll JS.

Mol Cell Endocrinol. 2017 Mar 5;443:175. doi: 10.1016/j.mce.2017.01.048. No abstract available.

PMID:
28183459
15.

MicroRNA-194 Promotes Prostate Cancer Metastasis by Inhibiting SOCS2.

Das R, Gregory PA, Fernandes RC, Denis I, Wang Q, Townley SL, Zhao SG, Hanson AR, Pickering MA, Armstrong HK, Lokman NA, Ebrahimie E, Davicioni E, Jenkins RB, Karnes RJ, Ross AE, Den RB, Klein EA, Chi KN, Ramshaw HS, Williams ED, Zoubeidi A, Goodall GJ, Feng FY, Butler LM, Tilley WD, Selth LA.

Cancer Res. 2017 Feb 15;77(4):1021-1034. doi: 10.1158/0008-5472.CAN-16-2529. Epub 2016 Dec 23.

16.

Comprehensive assessment of estrogen receptor beta antibodies in cancer cell line models and tissue reveals critical limitations in reagent specificity.

Nelson AW, Groen AJ, Miller JL, Warren AY, Holmes KA, Tarulli GA, Tilley WD, Katzenellenbogen BS, Hawse JR, Gnanapragasam VJ, Carroll JS.

Mol Cell Endocrinol. 2017 Jan 15;440:138-150. doi: 10.1016/j.mce.2016.11.016. Epub 2016 Nov 23. Erratum in: Mol Cell Endocrinol. 2017 Mar 5;443:175.

17.

Deciphering the divergent roles of progestogens in breast cancer.

Carroll JS, Hickey TE, Tarulli GA, Williams M, Tilley WD.

Nat Rev Cancer. 2017 Jan;17(1):54-64. doi: 10.1038/nrc.2016.116. Epub 2016 Nov 25. Review.

PMID:
27885264
18.

Novel twists in hormone-mediated carcinogenesis.

Tilley WD.

Endocr Relat Cancer. 2016 Dec;23(12):E9-E12. No abstract available.

PMID:
27836990
19.

Androgen receptor signaling in castration-resistant prostate cancer: a lesson in persistence.

Coutinho I, Day TK, Tilley WD, Selth LA.

Endocr Relat Cancer. 2016 Dec;23(12):T179-T197. Epub 2016 Oct 31. Review.

PMID:
27799360
20.

Pushing estrogen receptor around in breast cancer.

Lim E, Tarulli G, Portman N, Hickey TE, Tilley WD, Palmieri C.

Endocr Relat Cancer. 2016 Dec;23(12):T227-T241. Epub 2016 Oct 11. Review.

PMID:
27729416
21.

Renewed interest in the progesterone receptor in breast cancer.

Lim E, Palmieri C, Tilley WD.

Br J Cancer. 2016 Oct 11;115(8):909-911. doi: 10.1038/bjc.2016.303. Epub 2016 Sep 22. No abstract available.

22.

Androgen and Estrogen Receptors in Breast Cancer Coregulate Human UDP-Glucuronosyltransferases 2B15 and 2B17.

Hu DG, Selth LA, Tarulli GA, Meech R, Wijayakumara D, Chanawong A, Russell R, Caldas C, Robinson JL, Carroll JS, Tilley WD, Mackenzie PI, Hickey TE.

Cancer Res. 2016 Oct 1;76(19):5881-5893. Epub 2016 Aug 5.

23.

Genomic agonism and phenotypic antagonism between estrogen and progesterone receptors in breast cancer.

Singhal H, Greene ME, Tarulli G, Zarnke AL, Bourgo RJ, Laine M, Chang YF, Ma S, Dembo AG, Raj GV, Hickey TE, Tilley WD, Greene GL.

Sci Adv. 2016 Jun 24;2(6):e1501924. doi: 10.1126/sciadv.1501924. eCollection 2016 Jun.

24.

Small Glutamine-Rich Tetratricopeptide Repeat-Containing Protein Alpha (SGTA) Ablation Limits Offspring Viability and Growth in Mice.

Philp LK, Day TK, Butler MS, Laven-Law G, Jindal S, Hickey TE, Scher HI, Butler LM, Tilley WD.

Sci Rep. 2016 Jun 30;6:28950. doi: 10.1038/srep28950.

25.

A ZEB1-miR-375-YAP1 pathway regulates epithelial plasticity in prostate cancer.

Selth LA, Das R, Townley SL, Coutinho I, Hanson AR, Centenera MM, Stylianou N, Sweeney K, Soekmadji C, Jovanovic L, Nelson CC, Zoubeidi A, Butler LM, Goodall GJ, Hollier BG, Gregory PA, Tilley WD.

Oncogene. 2017 Jan 5;36(1):24-34. doi: 10.1038/onc.2016.185. Epub 2016 Jun 6.

PMID:
27270433
26.

Erratum to: IκBα mediates prostate cancer cell death induced by combinatorial targeting of the androgen receptor.

Carter SL, Centenera MM, Tilley WD, Selth LA, Butler LM.

BMC Cancer. 2016 Mar 3;16:177. doi: 10.1186/s12885-016-2215-3. No abstract available.

28.

Choline Kinase Alpha as an Androgen Receptor Chaperone and Prostate Cancer Therapeutic Target.

Asim M, Massie CE, Orafidiya F, Pértega-Gomes N, Warren AY, Esmaeili M, Selth LA, Zecchini HI, Luko K, Qureshi A, Baridi A, Menon S, Madhu B, Escriu C, Lyons S, Vowler SL, Zecchini VR, Shaw G, Hessenkemper W, Russell R, Mohammed H, Stefanos N, Lynch AG, Grigorenko E, D'Santos C, Taylor C, Lamb A, Sriranjan R, Yang J, Stark R, Dehm SM, Rennie PS, Carroll JS, Griffiths JR, Tavaré S, Mills IG, McEwan IJ, Baniahmad A, Tilley WD, Neal DE.

J Natl Cancer Inst. 2015 Dec 11;108(5). doi: 10.1093/jnci/djv371. Print 2016 May.

29.

Regulators of genetic risk of breast cancer identified by integrative network analysis.

Castro MA, de Santiago I, Campbell TM, Vaughn C, Hickey TE, Ross E, Tilley WD, Markowetz F, Ponder BA, Meyer KB.

Nat Genet. 2016 Jan;48(1):12-21. doi: 10.1038/ng.3458. Epub 2015 Nov 30.

30.

Expression of androgen receptor splice variants in clinical breast cancers.

Hickey TE, Irvine CM, Dvinge H, Tarulli GA, Hanson AR, Ryan NK, Pickering MA, Birrell SN, Hu DG, Mackenzie PI, Russell R, Caldas C, Raj GV, Dehm SM, Plymate SR, Bradley RK, Tilley WD, Selth LA.

Oncotarget. 2015 Dec 29;6(42):44728-44. doi: 10.18632/oncotarget.6296.

31.

Hormone-sensing mammary epithelial progenitors: emerging identity and hormonal regulation.

Tarulli GA, Laven-Law G, Shakya R, Tilley WD, Hickey TE.

J Mammary Gland Biol Neoplasia. 2015 Jun;20(1-2):75-91. doi: 10.1007/s10911-015-9344-1. Epub 2015 Sep 21. Review.

PMID:
26390871
32.

Corrigendum: Progesterone receptor modulates ERα action in breast cancer.

Mohammed H, Russell IA, Stark R, Rueda OM, Hickey TE, Tarulli GA, Serandour AA, Birrell SN, Bruna A, Saadi A, Menon S, Hadfield J, Pugh M, Raj GV, Brown GD, D'Santos C, Robinson JL, Silva G, Launchbury R, Perou CM, Stingl J, Caldas C, Tilley WD, Carroll JS.

Nature. 2015 Oct 1;526(7571):144. doi: 10.1038/nature14959. Epub 2015 Aug 5. No abstract available.

PMID:
26245370
33.

Co-targeting AR and HSP90 suppresses prostate cancer cell growth and prevents resistance mechanisms.

Centenera MM, Carter SL, Gillis JL, Marrocco-Tallarigo DL, Grose RH, Tilley WD, Butler LM.

Endocr Relat Cancer. 2015 Oct;22(5):805-18. doi: 10.1530/ERC-14-0541. Epub 2015 Jul 17.

PMID:
26187127
34.

Progesterone receptor modulates ERα action in breast cancer.

Mohammed H, Russell IA, Stark R, Rueda OM, Hickey TE, Tarulli GA, Serandour AA, Birrell SN, Bruna A, Saadi A, Menon S, Hadfield J, Pugh M, Raj GV, Brown GD, D'Santos C, Robinson JL, Silva G, Launchbury R, Perou CM, Stingl J, Caldas C, Tilley WD, Carroll JS.

Nature. 2015 Jul 16;523(7560):313-7. doi: 10.1038/nature14583. Epub 2015 Jul 8. Erratum in: Nature. 2015 Oct 1;526(7571):144. Serandour, Aurelien A A[Corrected to Serandour, Aurelien A].

35.

Expression and localisation of c-kit and KITL in the adult human ovary.

Tuck AR, Robker RL, Norman RJ, Tilley WD, Hickey TE.

J Ovarian Res. 2015 May 26;8:31. doi: 10.1186/s13048-015-0159-x.

36.

Targeting chromatin binding regulation of constitutively active AR variants to overcome prostate cancer resistance to endocrine-based therapies.

Chan SC, Selth LA, Li Y, Nyquist MD, Miao L, Bradner JE, Raj GV, Tilley WD, Dehm SM.

Nucleic Acids Res. 2015 Jul 13;43(12):5880-97. doi: 10.1093/nar/gkv262. Epub 2015 Apr 23.

37.

Epithelial plasticity in prostate cancer: principles and clinical perspectives.

Das R, Gregory PA, Hollier BG, Tilley WD, Selth LA.

Trends Mol Med. 2014 Nov;20(11):643-51. doi: 10.1016/j.molmed.2014.09.004. Epub 2014 Sep 25. Review.

PMID:
25262538
38.

Acquired convergence of hormone signaling in breast cancer: ER and PR transition from functionally distinct in normal breast to predictors of metastatic disease.

Hilton HN, Doan TB, Graham JD, Oakes SR, Silvestri A, Santucci N, Kantimm S, Huschtscha LI, Ormandy CJ, Funder JW, Simpson ER, Kuczek ES, Leedman PJ, Tilley WD, Fuller PJ, Muscat GE, Clarke CL.

Oncotarget. 2014 Sep 30;5(18):8651-64.

39.

Bringing androgens up a NOTCH in breast cancer.

Tarulli GA, Butler LM, Tilley WD, Hickey TE.

Endocr Relat Cancer. 2014 Aug;21(4):T183-202. doi: 10.1530/ERC-14-0248. Epub 2014 Jul 7. Review.

PMID:
25001242
40.

Mouse GDF9 decreases KITL gene expression in human granulosa cells.

Tuck AR, Mottershead DG, Fernandes HA, Norman RJ, Tilley WD, Robker RL, Hickey TE.

Endocrine. 2015 Mar;48(2):686-95. doi: 10.1007/s12020-014-0335-6. Epub 2014 Jul 2.

PMID:
24985063
41.

Complexities of androgen receptor signalling in breast cancer.

McNamara KM, Moore NL, Hickey TE, Sasano H, Tilley WD.

Endocr Relat Cancer. 2014 Aug;21(4):T161-81. doi: 10.1530/ERC-14-0243. Epub 2014 Jun 20. Review.

PMID:
24951107
42.

PRMT2 and RORγ expression are associated with breast cancer survival outcomes.

Oh TG, Bailey P, Dray E, Smith AG, Goode J, Eriksson N, Funder JW, Fuller PJ, Simpson ER, Tilley WD, Leedman PJ, Clarke CL, Grimmond S, Dowhan DH, Muscat GE.

Mol Endocrinol. 2014 Jul;28(7):1166-85. doi: 10.1210/me.2013-1403. Epub 2014 Jun 9.

43.

Human seminal fluid as a source of prostate cancer-specific microRNA biomarkers.

Selth LA, Roberts MJ, Chow CW, Marshall VR, Doi SA, Vincent AD, Butler LM, Lavin MF, Tilley WD, Gardiner RA.

Endocr Relat Cancer. 2014 Aug;21(4):L17-21. doi: 10.1530/ERC-14-0234. Epub 2014 May 23. No abstract available.

44.

Breast cancer prognosis predicted by nuclear receptor-coregulator networks.

Doan TB, Eriksson NA, Graham D, Funder JW, Simpson ER, Kuczek ES, Clyne C, Leedman PJ, Tilley WD, Fuller PJ, Muscat GE, Clarke CL.

Mol Oncol. 2014 Jul;8(5):998-1013. doi: 10.1016/j.molonc.2014.03.017. Epub 2014 Apr 4.

45.

Tailoring peptidomimetics for targeting protein-protein interactions.

Akram ON, DeGraff DJ, Sheehan JH, Tilley WD, Matusik RJ, Ahn JM, Raj GV.

Mol Cancer Res. 2014 Jul;12(7):967-78. doi: 10.1158/1541-7786.MCR-13-0611. Epub 2014 Mar 18. Review.

46.

Identification of androgen receptor splice variant transcripts in breast cancer cell lines and human tissues.

Hu DG, Hickey TE, Irvine C, Wijayakumara DD, Lu L, Tilley WD, Selth LA, Mackenzie PI.

Horm Cancer. 2014 Apr;5(2):61-71. doi: 10.1007/s12672-014-0171-4. Epub 2014 Feb 26.

PMID:
24570075
47.

Estrogen receptor beta in prostate cancer: friend or foe?

Nelson AW, Tilley WD, Neal DE, Carroll JS.

Endocr Relat Cancer. 2014 Aug;21(4):T219-34. doi: 10.1530/ERC-13-0508. Epub 2014 Jan 8. Review.

PMID:
24402043
48.

Elevated levels of FOXA1 facilitate androgen receptor chromatin binding resulting in a CRPC-like phenotype.

Robinson JL, Hickey TE, Warren AY, Vowler SL, Carroll T, Lamb AD, Papoutsoglou N, Neal DE, Tilley WD, Carroll JS.

Oncogene. 2014 Dec 11;33(50):5666-74. doi: 10.1038/onc.2013.508. Epub 2013 Dec 2.

49.

Distinct nuclear receptor expression in stroma adjacent to breast tumors.

Knower KC, Chand AL, Eriksson N, Takagi K, Miki Y, Sasano H, Visvader JE, Lindeman GJ, Funder JW, Fuller PJ, Simpson ER, Tilley WD, Leedman PJ, Graham J, Muscat GE, Clarke CL, Clyne CD.

Breast Cancer Res Treat. 2013 Nov;142(1):211-23.

PMID:
24122391
50.

Lack of high-dose radiation mediated prostate cancer promotion and low-dose radiation adaptive response in the TRAMP mouse model.

Lawrence MD, Ormsby RJ, Blyth BJ, Bezak E, England G, Newman MR, Tilley WD, Sykes PJ.

Radiat Res. 2013 Oct;180(4):376-88. doi: 10.1667/RR3381.2. Epub 2013 Aug 23.

PMID:
23971516

Supplemental Content

Loading ...
Support Center